www.nbcnews.com
The World Health Organization (WHO) now recommends glucagon-like peptide-1 receptor agonists (GLP-1 RAs), like semaglutide, as part of a comprehensive treatment plan for obesity in adults. This plan includes lifestyle modifications like diet, exercise, and psychological support. WHO emphasizes that these drugs are not a “magic bullet” but a potential tool, especially for those who haven’t achieved success with lifestyle changes alone. They also highlight the importance of accessibility, affordability, and integration into national health strategies, while cautioning against prioritizing cosmetic use over medical need. Careful patient selection, monitoring for side effects, and discontinuing the drug if significant weight loss isn’t achieved after a reasonable period are also crucial.
